Health In Tech, Inc. (HIT): Results of Operations and Financial Condition
Health In Tech, Inc. (HIT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030198001ex99-1.htm PRESS RELEASE DATED AUGUST 13, 2026 Exhibit 99.1 Health In Tech Reports Second Quarter 2026 Financial Results Contracted Revenue of $32.3 Million as of June 30, 2026 Pipeline Revenue of $66.3 Million as of July 31, 2026 Distribution Partners Grew 1
How this was made
The 30-second read
Why it matters
The filing updates investors on revenue trajectory, profitability, and forward revenue visibility via contracted revenue and pipeline revenue, while reaffirming full-year 2026 revenue guidance. It also provides quantified expectations for GAAP revenue recognition from pipeline quoting/binding status based on a stated conversion range.
Market read
Traders can use the new contracted and pipeline revenue metrics, the quantified GAAP recognition ranges, and the reaffirmed $45M to $50M 2026 guidance to reassess near-term risk/reward and positioning ahead of subsequent quarters.
What to watch
The text emphasizes conversion assumptions (15% to 40%) and GAAP recognition deferral from contracted revenue; traders should model sensitivity to conversion and the split between second-half 2026 and 2027 GAAP revenue recognition.
Background
This is an SEC Form 8-K (Item 2.02) with Exhibit 99.1 reporting unaudited Q2 2026 and first-half 2026 financial results for Health In Tech, plus outlook and product/program updates.
Ticker impact
Health In Tech reports Q2 2026 results, including revenue decline, net loss, and reaffirmed full-year 2026 revenue guidance of $45M to $50M.
Likely modest volatility around the guidance and pipeline conversion outlook, with downside risk if investors focus on GAAP revenue timing and Q2 revenue contraction.
The filing includes multiple new datapoints: Q2 revenue and net loss, contracted and pipeline revenue levels, and a quantified expected GAAP revenue recognition range for 2026-2027 based on stated conversion assumptions. However, it is not a surprise beat/miss narrative with explicit consensus comparisons in the text, so magnitude is uncertain.
Market effects
As an AI-enabled InsurTech platform, HIT’s disclosed pipeline conversion and distribution-partner growth can influence how traders price early-stage insurtech revenue visibility and GAAP timing risk.
No clear regional spillover beyond US-listed small-cap insurtech sentiment.
Limited, as the disclosure is company-specific and not tied to global macro or cross-border regulation in the provided text.
Counterpoint
Investors may overreact to GAAP revenue timing and Q2 contraction, while the larger contracted revenue book and quantified pipeline-to-contracted conversion could support stronger forward GAAP recognition in 2H 2026 and 2027.
Key entities
- companyHealth In Tech, Inc.
AI-enabled InsurTech platform company reporting Q2 2026 results and reaffirming 2026 revenue guidance.
- productHitRix
Next-generation marketplace platform expected to launch in 2H 2026, expanding AI use across the self-funded stop-loss ecosystem.
- programThree-Year Rate Stabilization Program
Employer-focused stop-loss pricing program; company says it secured its first employer group and expects capital-markets launch updates.
